TCGA-77-8008-01A-21R-2187-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.560
- WNT_BETA_CATENIN_SIGNALING+0.450
- IL6_JAK_STAT3_SIGNALING+0.440
- NOTCH_SIGNALING+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- UV_RESPONSE_DN+0.420
- APICAL_JUNCTION+0.410
- HYPOXIA+0.400
- HEDGEHOG_SIGNALING+0.380
Top 10 suppressed
- E2F_TARGETS-0.550
- OXIDATIVE_PHOSPHORYLATION-0.480
- MYC_TARGETS_V1-0.470
- MYC_TARGETS_V2-0.470
- G2M_CHECKPOINT-0.410
- SPERMATOGENESIS-0.360
- FATTY_ACID_METABOLISM-0.350
- DNA_REPAIR-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- MTORC1_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-6175-01A-11R-1820-07 | — | cohortSQ1 | 0.943 |
| 2 | TCGA-E9-A1NG-01A-21R-A14M-07 | — | A | 0.917 |
| 3 | C3N-03205 | — | cohortA1 | 0.916 |
| 4 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.913 |
| 5 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.907 |
| 6 | GSM6454738 | — | A | 0.900 |
| 7 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.896 |
| 8 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.896 |
| 9 | SRR17866819 | — | — | 0.893 |
| 10 | be66e85c-d70d-4073-af6a-bcee51ef3240 | — | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.450 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.410 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |